UCB stock gets new US manufacturing boost from $2 billion campus

Published on 10/31/2026 at 10:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

UCB stock heads into the weekend after a major expansion of its US manufacturing footprint. The project adds long-term capacity for biologic medicines.

UCB expands its US footprint

UCB is building a biologics manufacturing campus in Georgia with completion targeted for 2032 or 2033.
The project is expected to create 330 permanent jobs and strengthen UCB's US supply chain.
UCB's next scheduled financial catalyst is its full-year 2026 results and 2027 guidance on February 25, 2027.

UCB, BE0003739530, Illustration mit AI erstellt.

UCB is expanding its US manufacturing footprint with a new biologics campus in Georgia, adding a long-term industrial dimension to the Belgian drugmaker's growth strategy. The National Association of Manufacturers reported the project on October 23, 2026, citing Genetic Engineering & Biotechnology News and Contract Pharma.

The Rowen campus is expected to be completed in 2032 or 2033 and will produce biologic medicines using artificial intelligence, automation and advanced manufacturing technologies. UCB expects the site to create 330 permanent jobs and occupy approximately 460,000 square feet in Georgia's Rowen innovation district.

Capacity supports commercial ambitions

The investment is intended to strengthen UCB's US supply chain, where more than 2,000 employees already work, according to the National Association of Manufacturers. UCB Chief Executive Jean-Christophe Tellier said the project should support patients, scientific innovation and skilled employment.

The expansion comes after UCB raised its 2026 financial guidance on October 22. In its official release, the company cited stronger US demand for BIMZELX and continued volume growth for CIMZIA. UCB now expects 2026 revenue growth in the low twenties at constant exchange rates and adjusted EBITDA growth in the low-to-mid-forties range, excluding proceeds from a potential Priority Review Voucher sale.

The real-time quote of UCB stock was 279.45 euros on Lang & Schwarz at 10:18 CET on Saturday, October 31, 2026.

UCB at a glance

Company: UCB S.A.
ISIN: BE0003739530
Primary listing: Euronext Brussels
Lang & Schwarz quote: 279.45 euros, October 31, 2026, 10:18 CET
Next scheduled catalyst: Full-year 2026 results and 2027 guidance on February 25, 2027

For the wider market context, see current market reports.

More news and analyses on UCB stock.